Short answer
AbbVie Inc (ABBV) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $15.0B (up 12.4% year over year) with net income of $695M.
Q1 2026 key financials · XBRL
- Revenue
- $15.0B
- +12.4% YoY
- Net income
- $695M
- −46.0% YoY
- Operating margin
- 26.6%
- EPS (diluted)
- $0.39
- −45.8% YoY
Source: XBRL data from the AbbVie Inc (ABBV) Q1 2026 10-Q on SEC EDGAR. USD.
AbbVie Inc Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $15.002B, up 12.4% YoY from $13.343B
- Gross margin 72% vs 70%; effective tax rate 33% vs 22%
- Best product Skyrizi revenue $4.483B, up 30.9%; worst Humira revenue $688M, down 38.6%
- Operating cash flow $3.829B vs $1.635B; $8.0B debt issuance and $1.1B share repurchases
- Headwinds: Botox subject to Medicare price setting beginning 2028; Humira biosimilar competition continued
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AbbVie Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.